In the competitive field of medical devices, Edwards Lifesciences Corporation (EW) and STERIS plc (STE) stand out as influential players shaping healthcare innovation. Both companies deliver essential products and services that overlap in hospital and surgical environments, yet they pursue distinct strategies—Edwards focuses on structural heart solutions, while STERIS excels in infection prevention and sterilization technologies. This article will help you decide which company offers the best investment potential in 2026.
Table of contents
Companies Overview
I will begin the comparison between Edwards Lifesciences Corporation and STERIS plc by providing an overview of these two companies and their main differences.
Edwards Lifesciences Corporation Overview
Edwards Lifesciences Corporation specializes in products and technologies for structural heart disease and critical care monitoring. The company offers transcatheter heart valve replacement and repair systems, surgical heart solutions, and advanced hemodynamic monitoring tools. Headquartered in Irvine, California, Edwards operates globally, focusing on minimally invasive therapies and critical care technologies within the medical devices industry.
STERIS plc Overview
STERIS plc delivers infection prevention and procedural products globally across four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. Its offerings include cleaning chemistries, sterilizers, surgical equipment, and maintenance services for hospitals and pharmaceutical manufacturers. Founded in 1985 and based in Dublin, Ireland, STERIS emphasizes sterilization services and equipment essential for sterile processing and infection control in healthcare settings.
Key similarities and differences
Both companies operate in the medical devices sector with a focus on healthcare solutions, but their business models differ substantially. Edwards concentrates on cardiac care technologies and monitoring, while STERIS provides sterilization, infection prevention, and surgical equipment services. Edwards’ product portfolio targets heart valve therapies, whereas STERIS emphasizes sterilization technologies and procedural support across healthcare and life sciences industries.
Income Statement Comparison
The table below presents a side-by-side comparison of the most recent fiscal year income statement metrics for Edwards Lifesciences Corporation (EW) and STERIS plc (STE).
| Metric | Edwards Lifesciences Corporation (EW) | STERIS plc (STE) |
|---|---|---|
| Market Cap | 50B USD | 25.3B USD |
| Revenue | 5.44B USD | 5.46B USD |
| EBITDA | 1.72B USD | 1.36B USD |
| EBIT | 1.57B USD | 882M USD |
| Net Income | 4.17B USD | 615M USD |
| EPS | 6.98 USD | 6.24 USD |
| Fiscal Year | 2024 | 2025 |
Income Statement Interpretations
Edwards Lifesciences Corporation
Edwards Lifesciences showed a strong upward trend in revenue, growing from $4.39B in 2020 to $5.44B in 2024, accompanied by a remarkable net income increase from $823M to $4.17B. Margins remained robust, with a gross margin near 79.5% and net margin at 76.8% in 2024. The latest year saw favorable growth in earnings per share and net margin, despite slightly higher operating expenses.
STERIS plc
STERIS experienced steady revenue growth from $3.11B in 2021 to $5.46B in 2025, while net income rose from $397M to $615M. Margins were more moderate, with a 44% gross margin and 11.3% net margin in 2025. The most recent year showed a neutral revenue and EBIT growth but favorable improvements in net margin and earnings per share, offset by ongoing operational expense challenges.
Which one has the stronger fundamentals?
Edwards Lifesciences demonstrates stronger fundamentals with higher margin levels and more pronounced net income growth over the period. Its income statement shows 92.9% favorable indicators versus STERIS’s 71.4%, which, although positive, reflects more muted profitability and margin pressure. Both companies are growing, but Edwards’s superior efficiency and margin expansion stand out.
Financial Ratios Comparison
The table below presents the most recent financial ratios for Edwards Lifesciences Corporation and STERIS plc, illustrating key performance and financial health metrics as of their latest fiscal year-end.
| Ratios | Edwards Lifesciences Corporation (EW) | STERIS plc (STE) |
|---|---|---|
| ROE | 41.8% | 9.3% |
| ROIC | 10.7% | 7.2% |
| P/E | 10.6 | 36.3 |
| P/B | 4.43 | 3.38 |
| Current Ratio | 4.18 | 1.96 |
| Quick Ratio | 3.45 | 1.39 |
| D/E (Debt to Equity) | 0.07 | 0.33 |
| Debt-to-Assets | 5.4% | 21.7% |
| Interest Coverage | 69.6 | 10.0 |
| Asset Turnover | 0.42 | 0.54 |
| Fixed Asset Turnover | 3.05 | 2.58 |
| Payout ratio | 0 | 35.8% |
| Dividend yield | 0% | 0.98% |
Interpretation of the Ratios
Edwards Lifesciences Corporation
Edwards Lifesciences shows predominantly strong financial ratios, with favorable net margin at 76.75% and return on equity at 41.75%, indicating efficient profitability and shareholder value creation. Some concerns include an unfavorable price-to-book ratio of 4.43 and a high current ratio of 4.18, which might suggest less efficient asset use. The company does not pay dividends, likely due to reinvestment in R&D and growth initiatives, prioritizing long-term value over immediate shareholder returns.
STERIS plc
STERIS exhibits mixed financial ratios, with a favorable net margin of 11.26% but an unfavorable return on equity at 9.31%, reflecting moderate profitability and shareholder returns. The price-to-earnings ratio is high at 36.35, signaling potential overvaluation. The company pays dividends with a yield of 0.98%, supported by moderate coverage, but the yield is considered unfavorable compared to industry standards. Its balance sheet ratios are generally favorable, supporting operational stability.
Which one has the best ratios?
Edwards Lifesciences presents a more favorable overall ratio profile, including higher profitability metrics and stronger capital structure indicators. While STERIS shows some strengths, particularly in liquidity and interest coverage, its lower return on equity and higher valuation multiples temper its appeal. Thus, Edwards’ ratios suggest more robust financial health relative to STERIS.
Strategic Positioning
This section compares the strategic positioning of Edwards Lifesciences Corporation (EW) and STERIS plc (STE) regarding Market position, Key segments, and Exposure to technological disruption:
Edwards Lifesciences Corporation (EW)
- Leading medical devices company focused on structural heart disease with competitive pressure from innovative heart therapies.
- Key segments include transcatheter heart valves, surgical heart valve therapy, and critical care monitoring products driving growth.
- Exposure to technological disruption through minimally invasive heart valve replacements and advanced monitoring software.
STERIS plc (STE)
- Medical devices firm with diversified segments facing competitive pressure across infection prevention and sterilization markets.
- Operates four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental, with balanced product and service revenues.
- Moderate exposure via sterilization technologies and equipment management services supporting healthcare and pharmaceutical sectors.
Edwards Lifesciences Corporation vs STERIS plc Positioning
EW has a concentrated focus on innovative heart valve therapies and critical care, benefiting from specialized product leadership. STE’s diversified approach spans sterilization, healthcare equipment, and services, providing broader market coverage but less specialization in any one area.
Which has the best competitive advantage?
EW demonstrates a slightly favorable economic moat by creating value despite a declining ROIC trend. STE shows a slightly unfavorable moat, shedding value but with improving profitability, indicating EW currently holds a stronger competitive advantage.
Stock Comparison
The past year’s stock price movements reveal contrasting dynamics between Edwards Lifesciences Corporation and STERIS plc, with notable acceleration in trends and varying degrees of volatility shaping their respective performances.
Trend Analysis
Edwards Lifesciences Corporation’s stock showed a slight bearish trend over the past 12 months with a -1.13% price change, accompanied by accelerating decline and moderate volatility (std deviation 8.32). Recent months indicate a bullish rebound of 11.87%.
STERIS plc experienced a strong bullish trend over the same period, gaining 11.07% with accelerating momentum and higher volatility (std deviation 14.87). Its recent trend remains positive with a 6.67% increase.
Comparing both, STERIS plc delivered the highest market performance over the last year, outperforming Edwards Lifesciences Corporation in overall price appreciation despite the latter’s recent upward correction.
Target Prices
Analysts present a clear target price consensus for Edwards Lifesciences Corporation and STERIS plc.
| Company | Target High | Target Low | Consensus |
|---|---|---|---|
| Edwards Lifesciences Corporation | 108 | 87 | 96.47 |
| STERIS plc | 265 | 245 | 256.67 |
The target consensus for Edwards Lifesciences is moderately above its current price of 85.13 USD, suggesting potential upside. STERIS’s consensus target closely aligns with its current price of 256.82 USD, indicating limited near-term price movement expectation.
Analyst Opinions Comparison
This section compares analysts’ ratings and grades for Edwards Lifesciences Corporation (EW) and STERIS plc (STE):
Rating Comparison
EW Rating
- Rating: A- indicating a very favorable overall assessment
- Discounted Cash Flow Score: 4, favorable evaluation of future cash flows
- ROE Score: 4, favorable efficiency in generating profit from equity
- ROA Score: 5, very favorable asset utilization
- Debt To Equity Score: 3, moderate financial risk level
- Overall Score: 4, favorable overall financial standing
STE Rating
- Rating: B indicating a very favorable overall assessment
- Discounted Cash Flow Score: 4, favorable evaluation of future cash flows
- ROE Score: 3, moderate efficiency in generating profit from equity
- ROA Score: 4, favorable asset utilization
- Debt To Equity Score: 2, moderate financial risk level
- Overall Score: 3, moderate overall financial standing
Which one is the best rated?
Based strictly on provided data, Edwards Lifesciences (EW) holds a higher rating (A-) and better overall and ROA scores than STERIS (STE), which has a B rating and generally lower scores. EW is thus better rated.
Scores Comparison
Here is a comparison of the key financial scores for Edwards Lifesciences Corporation (EW) and STERIS plc (STE):
EW Scores
- Altman Z-Score: 12.28, indicating a safe zone and low bankruptcy risk.
- Piotroski Score: 5, classified as average financial strength.
STE Scores
- Altman Z-Score: 5.91, indicating a safe zone and low bankruptcy risk.
- Piotroski Score: 8, classified as very strong financial strength.
Which company has the best scores?
STE has a lower Altman Z-Score than EW but both are in the safe zone. STE’s Piotroski Score of 8 is notably stronger than EW’s average score of 5, indicating better financial strength for STE based on the provided data.
Grades Comparison
Here is a comparison of the latest reliable grades for Edwards Lifesciences Corporation and STERIS plc:
Edwards Lifesciences Corporation Grades
The following table shows recent grades from reputable grading companies for Edwards Lifesciences Corporation:
| Grading Company | Action | New Grade | Date |
|---|---|---|---|
| TD Cowen | Buy | Buy | 2026-01-09 |
| Stifel | Maintain | Buy | 2026-01-07 |
| JP Morgan | Upgrade | Overweight | 2025-12-18 |
| Canaccord Genuity | Maintain | Hold | 2025-12-17 |
| Baird | Maintain | Neutral | 2025-12-16 |
| Citigroup | Maintain | Buy | 2025-12-11 |
| Barclays | Maintain | Overweight | 2025-12-08 |
| Truist Securities | Maintain | Hold | 2025-12-05 |
| Canaccord Genuity | Maintain | Hold | 2025-12-05 |
| UBS | Maintain | Neutral | 2025-12-05 |
Edwards Lifesciences shows a positive trend with multiple buy and overweight ratings alongside several hold and neutral grades, indicating balanced but generally favorable analyst sentiment.
STERIS plc Grades
The following table presents the recent grades provided by recognized grading firms for STERIS plc:
| Grading Company | Action | New Grade | Date |
|---|---|---|---|
| Morgan Stanley | Maintain | Overweight | 2025-08-08 |
| Keybanc | Maintain | Overweight | 2025-07-22 |
| Morgan Stanley | Upgrade | Overweight | 2025-07-15 |
| Morgan Stanley | Maintain | Equal Weight | 2025-05-19 |
| JMP Securities | Maintain | Market Outperform | 2025-05-16 |
| Stephens & Co. | Maintain | Overweight | 2025-05-15 |
| Morgan Stanley | Maintain | Equal Weight | 2025-05-12 |
| JMP Securities | Maintain | Market Outperform | 2025-04-10 |
| Needham | Maintain | Hold | 2025-04-07 |
| JMP Securities | Maintain | Market Outperform | 2025-02-06 |
STERIS plc maintains a strong consensus with several overweight and market outperform ratings, suggesting sustained positive analyst confidence.
Which company has the best grades?
Both Edwards Lifesciences and STERIS plc hold consensus “Buy” ratings, but Edwards has a greater number of buy ratings (32 vs. 11) and a wider range of recent upgrades, reflecting more pronounced analyst enthusiasm. This could translate to stronger investor interest and potential momentum for Edwards compared to STERIS.
Strengths and Weaknesses
Below is a comparison table summarizing key strengths and weaknesses of Edwards Lifesciences Corporation (EW) and STERIS plc (STE) based on the most recent financial and operational data.
| Criterion | Edwards Lifesciences Corporation (EW) | STERIS plc (STE) |
|---|---|---|
| Diversification | Focused on heart valve therapies with growing segments in transcatheter devices; limited diversification outside core cardiac products. | Balanced revenue split between products and services, providing stable cash flow and operational flexibility. |
| Profitability | High net margin (76.75%) and ROIC (10.72%), indicating strong profitability; however, ROIC trend is declining. | Moderate net margin (11.26%) and ROIC (7.17%), with improving ROIC trend signaling growing profitability. |
| Innovation | Leading in transcatheter heart valve innovation, driving revenue growth in advanced therapies. | Innovation centered on sterilization and infection prevention; steady but less dynamic compared to EW. |
| Global presence | Strong global footprint in cardiovascular devices with expanding international sales. | Extensive global presence in healthcare and life sciences sectors, supported by diversified product/service base. |
| Market Share | Leading market share in heart valve therapies, especially in transcatheter valves segment. | Solid market share in sterilization and surgical equipment markets, but facing competitive pressure. |
In summary, Edwards Lifesciences excels in profitability and innovation within a specialized niche but shows a declining return trend, while STERIS offers better diversification and improving profitability, though with lower margins. Investors should weigh EW’s strong competitive moat against STE’s balanced portfolio and growth potential.
Risk Analysis
Below is a comparative table outlining key risks for Edwards Lifesciences Corporation (EW) and STERIS plc (STE) based on the most recent data available for 2025-2026.
| Metric | Edwards Lifesciences Corporation (EW) | STERIS plc (STE) |
|---|---|---|
| Market Risk | Moderate beta 0.955; stable healthcare demand but sensitive to innovation cycles | Slightly higher beta 1.032; exposure to healthcare procedural demand fluctuations |
| Debt level | Very low leverage: Debt-to-equity 0.07, Debt-to-assets 5.36% (favorable) | Moderate leverage: Debt-to-equity 0.33, Debt-to-assets 21.71% (favorable but higher) |
| Regulatory Risk | High due to medical device approvals and compliance globally | High, given sterilization standards and healthcare regulations worldwide |
| Operational Risk | Moderate; relies on cutting-edge tech and supply chain efficiency | Moderate; complex operations across multiple segments and global facilities |
| Environmental Risk | Low to moderate; medical device manufacturing with regulatory environmental standards | Moderate; sterilization chemicals and processes pose environmental challenges |
| Geopolitical Risk | Moderate; US-based with international markets, potential trade/tariff impacts | Elevated; headquartered in Ireland with global operations, exposure to trade policies |
The most impactful and likely risks for both companies are regulatory challenges in the healthcare sector, which can delay product approvals or increase compliance costs. Edwards Lifesciences benefits from very low debt, reducing financial risk, while STERIS carries more debt but maintains good interest coverage. Geopolitical tensions and environmental regulations also warrant attention given their global operations. Overall, both companies show resilience but require vigilance on regulatory and geopolitical fronts.
Which Stock to Choose?
Edwards Lifesciences Corporation (EW) shows strong income growth with a 24% revenue increase over 2020-2024 and very favorable profitability metrics, including a 76.75% net margin and 41.75% ROE. Its debt is low, with a 0.07 debt-to-equity ratio, and the overall rating is very favorable (A-).
STERIS plc (STE) presents moderate income growth of 75.69% over 2021-2025 but with lower profitability, evidenced by an 11.26% net margin and 9.31% ROE, though its debt ratios remain favorable. The rating is very favorable (B), supported by a very strong Piotroski score.
For investors prioritizing high profitability and strong financial stability, EW could appear more attractive given its favorable income statement and rating. Conversely, STE might appeal to those valuing growth potential and improving profitability despite its slightly less robust financial ratios and valuation metrics.
Disclaimer: Investment carries a risk of loss of initial capital. The past performance is not a reliable indicator of future results. Be sure to understand risks before making an investment decision.
Go Further
I encourage you to read the complete analyses of Edwards Lifesciences Corporation and STERIS plc to enhance your investment decisions:
